Literature DB >> 25696252

Quality of secondary cardiovascular prevention in specialised care in the Netherlands: the SOLID study.

M M van Galen, J J C Jonker, F Vermeer, D E Grobbee.   

Abstract

OBJECTIVE: To determine the extent to which Dutch patients with a history of cardiovascular disease and high cholesterol levels, treated in specialised care, are achieving low-cholesterol targets as defined by national guidelines.
DESIGN: Hospital-based cohort study.
SETTING: Practices of 41 hospital-based cardiologists and internists in the Netherlands.
SUBJECTS: 7377 patients.
RESULTS: Forty-one percent of the patients with an indication for secondary cardiovascular prevention by lipid-lowering drug treatment were receiving medication and were achieving cholesterol targets, 42% were receiving lipid-lowering medication but had cholesterol levels above target, 11% were not receiving treatment, and 5% had no recent lipid measurements.
CONCLUSION: Compared with previous studies, the SOLID study shows that a relatively large percentage of the Dutch patients under specialised care with a history of cardiovascular disease and an indication for cholesterol-reducing therapy are currently being treated. A considerable proportion of the patients, however, are still not receiving optimal treatment and more than 10% are not being treated at all.

Entities:  

Keywords:  Dutch guidelines; cardiovascular disease; high cholesterol levels

Year:  2004        PMID: 25696252      PMCID: PMC2497041     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  6 in total

1.  [Prevalence and treatment of hypercholesterolemia in patients with manifest vascular disease according to practice guidelines of the current cholesterol consensus].

Authors:  M F van de Laak; Y van der Graaf; J D Banga; P C Simons; A Algra
Journal:  Ned Tijdschr Geneeskd       Date:  2000-04-08

Review 2.  Cholesterol risk management: a systematic examination of the gap from evidence to practice.

Authors:  K L Olson; T J Bungard; R T Tsuyuki
Journal:  Pharmacotherapy       Date:  2001-07       Impact factor: 4.705

3.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

4.  Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

5.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

6.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.